Valuation: Tonix Pharmaceuticals Holding Corp.

Market Cap 160M 139M 129M 119M 224M 15.21B 228M 1.53B 598M 7.58B 599M 586M 25.02B P/E 2026 *
-1x
P/E 2027 * -1.59x
Enterprise Value 160M 139M 129M 119M 224M 15.21B 228M 1.53B 598M 7.58B 599M 586M 25.02B EV / Sales 2026 *
4.67x
EV / Sales 2027 * 2.02x
Free-Float
99.86%
Yield 2026 *
-
Yield 2027 * -
08:35pm Tonix Pharmaceuticals Announces Positive Minutes From Type C FDA Meeting To Discuss Adaptive Phase 2 Field Study Of TNX-4800, A Human, Anti-OspA Monoclonal Antibody, To Prevent Lyme Disease In The US CI
07-21 Tonix Pharmaceuticals Holding Corp. Announces Retirement of Gregory M. Sullivan as Chief Medical Officer, Effective August 20, 2026 CI
07-15 Tonix Pharmaceuticals Advances Tnx-801 Live Attenuated Minimally Replicative Investigational Vaccine Candidate Based on Horsepox Virus to Protect Against Mpox Disease CI
07-13 Tonix Pharmaceuticals Holding Corp. Announces Major Managed Medicare Agreement for Tonmya and Expands Pharmacy Coverage CI
07-13 Tonix Pharmaceuticals Reaches Medicare Coverage Deal for Fibromyalgia Treatment MT
06-29 Tonix Pharmaceuticals Advances TNX-102 SL Into Phase 2 MDD Study MT
06-29 Tonix Pharmaceuticals Holding Corp Announces First Patient Enrolled in Phase 2 Horizon Study of TNX-102 SL For Major Depressive Disorder CI
06-25 Raymond James Initiates Coverage on Tonix Pharmaceuticals With Strong Buy Rating, $26 PT MT
06-08 Tonix Pharmaceuticals Enters Second Commercial Payer Deal, Expands Drug Coverage MT
06-08 Tonix Pharmaceuticals Holding Corp. Enters Agreement With Group Purchasing Organization For Commercial Coverage Of TONMYA CI
05-28 Tonix Pharmaceuticals Holding Corp. Presents Data from Real-World Claims Analysis of Opioid Use in U.S. Adults with Fibromyalgia at 2026 ASCP Annual Meeting CI
05-27 Tonix Pharmaceuticals Holding Corp. Announces Publication Of Phase 1 Clinical Data Of TNX-1500 Fc-Modified Anti-CD40L Monoclonal Antibody CI
05-26 Tonix Pharmaceuticals Presents Real-World Claims Analysis And Launches TONMYA For Fibromyalgia Treatment CI

Last Transcript: Tonix Pharmaceuticals Holding Corp.

1 day+4.45%
1 week+2.84%
Current month+6.54%
1 month-16.09%
3 months-18.15%
6 months-37.85%
Current year-31.72%
1 week 9.4
Extreme 9.4
10.69
1 month 9.4
Extreme 9.4
13.19
Current year 9.4
Extreme 9.4
19.95
1 year 9.4
Extreme 9.4
69.97
3 years 6.76
Extreme 6.76
3,520
5 years 6.76
Extreme 6.76
521,600
10 years 6.76
Extreme 6.76
1,000,000
Manager TitleAgeSince
Chief Executive Officer 68 16/11/2007
Director of Finance/CFO 52 01/02/2016
Chief Tech/Sci/R&D Officer 57 04/02/2025
Director TitleAgeSince
Chairman 68 01/10/2011
Director/Board Member 66 12/09/2017
Director/Board Member 81 05/09/2018
Date Insider Type Main position Quantity % Market Cap.
6/30/26 A Others

Chief Financial Officer

1,453 0.0123%
3/31/26 A Buy

Chief Executive Officer

5,000 0.0425%
2/24/26 A Free

Chief Operating Officer

78,023 0.6625%
Change 5-day change 1-year change 3-year change Capi.($)
+6.54%+2.84%-76.11%-99.67% 160M
-2.39%-6.36%+45.82%+149.66% 1,024B
-0.76%-4.34%+48.74%+49.09% 618B
-2.33%-4.60%+24.30%+64.44% 443B
+0.68%+0.25%+38.47%+31.95% 349B
-1.66%-1.89%+32.18%+37.17% 297B
-8.96%-9.23%+3.57%+3.64% 264B
-1.37%-5.71%-2.10%-44.43% 209B
-1.63%+0.69%+25.48%+64.23% 208B
+0.72%+0.48%+14.53%+73.64% 162B
Average -1.42%-1.08%+15.49%+32.97% 357.39B
Weighted average by Cap. -1.96%-2.17%+33.28%+70.33%

Financials

2026 *2027 *
Net sales 34.18M 29.71M 27.74M 25.46M 48.01M 3.26B 48.85M 327M 128M 1.62B 128M 126M 5.36B 78.93M 68.6M 64.05M 58.8M 111M 7.52B 113M 755M 296M 3.75B 296M 290M 12.38B
Net income -170M -148M -138M -127M -239M -16.2B -243M -1.63B -637M -8.08B -638M -624M -26.65B -152M -132M -123M -113M -213M -14.47B -217M -1.45B -569M -7.22B -570M -558M -23.8B
Net Debt - -
Logo Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Employees
142
Date Price Change Volume
03/08/26 $10.67 +6.54% 343,107
31/07/26 $10.01 -0.79% 468,293
30/07/26 $10.09 +6.10% 329,107
29/07/26 $9.510 -4.33% 544,588
28/07/26 $9.940 -4.15% 452,312
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
10.01USD
Average target price
42.20USD
Spread / Average Target
+321.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TNXP Stock